610,804 Shares in Progyny, Inc. $PGNY Purchased by Nuveen LLC

Key Points

• Nuveen LLC acquired 610,804 shares of Progyny, Inc. for approximately $13.65 million, representing about 0.71% of the company's stock as of its latest SEC filing.
• Progyny reported $0.19 EPS, missing the consensus estimate of $0.42, but its revenue for the quarter was up 9.5% year-over-year, reaching $332.87 million.
• Analysts have set a consensus target price of $25.10 for Progyny, with ratings ranging from "Strong Buy" to "Hold" from various research firms.

Nuveen LLC purchased a new stake in Progyny, Inc. (NASDAQ:PGNY - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 610,804 shares of the company's stock, valued at approximately $13,645,000. Nuveen LLC owned approximately 0.71% of Progyny as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in PGNY. Wells Fargo & Company MN grew its position in Progyny by 37.8% during the fourth quarter. Wells Fargo & Company MN now owns 39,593 shares of the company's stock worth $683,000 after buying an additional 10,856 shares in the last quarter. Cerity Partners LLC bought a new stake in shares of Progyny in the 4th quarter valued at about $229,000. Invesco Ltd. lifted its stake in shares of Progyny by 2.9% in the 4th quarter. Invesco Ltd. now owns 274,819 shares of the company's stock valued at $4,741,000 after acquiring an additional 7,845 shares during the last quarter. Marshall Wace LLP bought a new position in Progyny during the 4th quarter valued at approximately $5,447,000. Finally, First Trust Advisors LP raised its position in Progyny by 13.1% during the 4th quarter. First Trust Advisors LP now owns 24,105 shares of the company's stock valued at $416,000 after purchasing an additional 2,794 shares during the last quarter. 94.93% of the stock is currently owned by hedge funds and other institutional investors.

Progyny Stock Down 3.3%

Shares of PGNY traded down $0.77 during trading hours on Tuesday, reaching $22.37. 299,891 shares of the company traded hands, compared to its average volume of 1,401,890. The stock has a market capitalization of $1.92 billion, a P/E ratio of 37.90, a P/E/G ratio of 1.92 and a beta of 1.32. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $26.76. The business has a fifty day moving average price of $22.59 and a 200-day moving average price of $22.18.

Progyny (NASDAQ:PGNY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing analysts' consensus estimates of $0.42 by ($0.23). Progyny had a net margin of 4.28% and a return on equity of 10.69%. The company had revenue of $332.87 million for the quarter, compared to analysts' expectations of $315.70 million. During the same period last year, the firm earned $0.17 earnings per share. Progyny's quarterly revenue was up 9.5% compared to the same quarter last year. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. As a group, research analysts predict that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Insider Buying and Selling at Progyny

In other news, Director Cheryl Scott sold 2,675 shares of the stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $22.07, for a total transaction of $59,037.25. Following the sale, the director directly owned 14,112 shares of the company's stock, valued at $311,451.84. This represents a 15.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Kevin K. Gordon sold 2,500 shares of the stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $22.04, for a total transaction of $55,100.00. Following the sale, the director directly owned 12,501 shares in the company, valued at approximately $275,522.04. The trade was a 16.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently weighed in on PGNY shares. JPMorgan Chase & Co. upped their price target on Progyny from $23.00 to $25.00 and gave the stock a "neutral" rating in a research note on Tuesday. Leerink Partnrs raised Progyny from a "hold" rating to a "strong-buy" rating in a report on Tuesday, July 8th. Wall Street Zen upgraded Progyny from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Canaccord Genuity Group boosted their target price on Progyny from $21.00 to $23.00 and gave the company a "hold" rating in a research report on Wednesday, August 20th. Finally, Truist Financial lifted their price target on shares of Progyny from $24.00 to $27.00 and gave the company a "hold" rating in a research note on Thursday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $25.30.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.